Download PDF
Neuropediatrics 1982; 13(2): 59-62
DOI: 10.1055/s-2008-1059598
ORIGINAL ARTICLES

© Georg Thieme Verlag KG Stuttgart · New York

Trial of an ACTH4-9 Analogue (ORG 2766) in Children with Intractable Seizures

K.  Pentella1 , D. S. Bachman2 , Curt A. Sandman3
  • 1Department of Medicine, Division of Neurology, Ohio State University, Columbus, Ohio 43210, USA
  • 2Department of Pediatrics, Division of Pediatric Neurology, Columbus Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, USA
  • 3Department of Psychology, Ohio State University, Columbus, Ohio 43210, USA
Further Information

Publication History

Publication Date:
19 March 2008 (online)

  PDF Download  Permissions and Reprints

Abstract

The ACTH4-9 Analogue (ORG 2766) is an orally administered neuropeptide which has been shown to have behavioral effects in human subjects, but does not have any steroidogenic effects, nor other significant side effects. This study was a double-blind, crossover trial of the ACTH4-9 analogue in four children with intractable seizures. There was some slight improvement in seizure frequency in two patients, with an equivocal improvement in a third child. A fourth child was unchanged, while the fifth dropped out of the study. There were no side effects from the therapy. This questionable improvement in seizure frequency in some of the most intractable patients with seizure disorders indicates the need to further assess this ACTH4-9 analogue in a larger study over a longer period of time.

Key words

Seizures, ACTH4-9 - Neuropeptides - ACTH fragments

      >